NDA 021777 · Teva Pharms Intl
Amrix
Cyclobenzaprine Hydrochloride · Oral
Last checked: Nov 20, 2026Latest source record: Apr 25, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2007
Feb 1, 2007
Approved uses
1
Original approval plus efficacy supplements
Registered trials
57
23 Phase 3, 6 recruiting
FAERS reports
9,077
5,296 serious, 754 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 1, 2026.
Cyclobenzaprine hydrochloride extended-release capsules are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, and limitation of motion. Limitations of Use: Cyclobenzaprine hydrochloride extended-release capsules should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride extended-release capsules have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease or in children with cerebral palsy. Cyclobenzaprine hydrochloride extended-release capsules are a muscle relaxant indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, and limitation of motion. ( 1 ) Limitations of Use: Cyclobenzaprine hydrochloride extended-release capsules should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. ( 1 ) Cyclobenzaprine hydrochloride extended-release capsules have not been found effective in the...
Mechanism: Cyclobenzaprine relieves skeletal muscle spasm of local origin without interfering with muscle function. Cyclobenzaprine has not been shown to be effective in muscle spasm due to central nervous system disease. In animal models, cyclobenzaprine reduced or abolished skeletal muscle hyperactivity. Animal studies indicate that cyclobenzaprine does not act at the neuromuscular junction or directly on skeletal muscle. Such studies show that cyclobenzaprine acts primarily within the central nervous system at the brain stem as opposed to the spinal cord level, although an overlapping action on the...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- AMRIX · CYCLOBENZAPRINE HYDROCHLORIDE 15MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
- AMRIX · CYCLOBENZAPRINE HYDROCHLORIDE 30MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Cyclobenzaprine" as an intervention, any sponsor and status, largest first.
- An Effectiveness and Safety Study of Cyclobenzaprine HCl Alone or in Combination With Ibuprofen for Acute Back or Neck Muscle Pain With Muscle SpasmPivotal-lookingCompleted
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.Industry
NCT00246389 · 1,000 participants
Drug: cyclobenzaprine hydrochloride · For: Pain; Spasm
- A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgiaPivotal-lookingCompleted
Tonix Pharmaceuticals, Inc.Industry
NCT02436096 · 519 participants · Start Apr 2015 · Primary completion Sep 2016
Drug: TNX-102 SL Tablet, 2.8mg; Placebo SL Tablet · For: Fibromyalgia; Myofascial Pain Syndromes; Muscular Diseases and 4 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Sacramento, California · 35 sites in all
- A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With FibromyalgiaPivotal-lookingCompleted
Tonix Pharmaceuticals, Inc.Industry
NCT04508621 · 514 participants · Start Jul 22, 2020 · Primary completion Nov 1, 2021
Drug: TNX-102 SL; Placebo SL Tablet · For: Fibromyalgia
Sites: Birmingham, Alabama; Phoenix, Arizona; Oceanside, California · 36 sites in all
- A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With FibromyalgiaPivotal-lookingCompleted
Tonix Pharmaceuticals, Inc.Industry
NCT04172831 · 503 participants · Start Dec 9, 2019 · Primary completion Oct 29, 2020
Drug: TNX-102 SL; Placebo SL Tablet · For: Fibromyalgia
Sites: Birmingham, Alabama; Phoenix, Arizona; Oceanside, California · 39 sites in all
- An Artificial Intelligence Driven Approach to Optimize Patient Selection for a Transitional Pain ServicePivotal-lookingNot yet recruiting
University of California, San FranciscoAcademic, hospital or other
NCT07296770 · 474 participants (planned) · Start Oct 1, 2026 · Primary completion Dec 1, 2028
Drug: Pharmacologic Pain Management · For: Postsurgical Pain Management; Postsurgical Pain, Chronic; Opioid Use After Surgery
Sites: San Francisco, California
- A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With FibromyalgiaPivotal-lookingCompleted
Tonix Pharmaceuticals, Inc.Industry
NCT05273749 · 457 participants · Start Apr 6, 2022 · Primary completion Nov 14, 2023
Drug: TNX-102 SL Tablet, 5.6 mg; Placebo SL Tablet · For: Fibromyalgia
Sites: Phoenix, Arizona; Oceanside, California; Santa Ana, California · 33 sites in all
- Efficacy and Safety of the Combination of Ketoprofen and Cyclobenzaprine in Osteomuscular TreatmentPivotal-lookingCompleted
EMSIndustry
NCT03025113 · 416 participants · Start Mar 8, 2018 · Primary completion Nov 29, 2019
Drug: ketoprofen and cyclobenzaprine association; Cyclobenzaprine · For: Musculoskeletal Pain
Sites: Campinas, Brazil
- Efficacy and Safety of the Combination of Ketoprofen and Cyclobenzaprine and Caffeine in Osteomuscular TreatmentPivotal-lookingCompleted
EMSIndustry
NCT02862977 · 414 participants · Start Nov 10, 2017 · Primary completion Jun 5, 2019
Drug: ketoprofen and cyclobenzaprine association with caffeine; Cyclobenzaprine with caffeine · For: Musculoskeletal Pain
Sites: Porto Alegre, Brazil; Campinas, Brazil; Jaú, Brazil · 6 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pain1,423
- headache1,112
- fatigue1,089
- drug ineffective833
- off label use749
- nausea746
- constipation715
- back pain657
- fall635
- dyspnoea576
- rheumatoid arthritis555
- diarrhoea539
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 119 |
| 2005 | 123 |
| 2006 | 110 |
| 2007 | 10 |
| 2008 | 35 |
| 2009 | 114 |
| 2010 | 119 |
| 2011 | 138 |
| 2012 | 116 |
| 2013 | 188 |
| 2014 | 139 |
| 2015 | 192 |
| 2016 | 292 |
| 2017 | 266 |
| 2018 | 339 |
| 2019 | 353 |
| 2020 | 512 |
| 2021 | 631 |
| 2022 | 928 |
| 2023 | 948 |
| 2024 | 1,159 |
| 2025 | 1,244 |
| 2026 | 1,001 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Amrix (Cyclobenzaprine HCl)
2024 spending
$448K
Beneficiaries
33
148 claims
Per beneficiary
$13,576
$55.64 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,243,843 |
| 2021 | $844,798 |
| 2022 | $593,872 |
| 2023 | $577,360 |
| 2024 | $448,018 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Long-Term Use of Muscle Relaxant Medications for Chronic Pain: A Systematic Review.
Oldfield BJ, Gleeson B, Morford KL, et al. · JAMA Netw Open 2024 · Systematic Review, Research Support, N.I.H., Extramural
- Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review.
Chou R, Peterson K, Helfand M · J Pain Symptom Manage 2004 · Comparative Study, Evaluation Study
- Pain relief by targeting nonrestorative sleep in fibromyalgia: a phase 3 randomized trial of bedtime sublingual cyclobenzaprine.
Lederman S, Arnold LM, Vaughn B, et al. · Pain Med 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Efficacy and Safety of Sublingual Cyclobenzaprine for the Treatment of Fibromyalgia: Results From a Randomized, Double-Blind, Placebo-Controlled Trial.
Lederman S, Arnold LM, Vaughn B, et al. · Arthritis Care Res (Hoboken) 2023 · Clinical Trial, Phase III, Randomized Controlled Trial
- Cyclobenzaprine for the treatment of myofascial pain in adults.
Leite FM, Atallah AN, El Dib R, et al. · Cochrane Database Syst Rev 2009 · Meta-Analysis, Systematic Review
- Cyclobenzaprine and back pain: a meta-analysis.
Browning R, Jackson JL, O'Malley PG · Arch Intern Med 2001 · Meta-Analysis, Systematic Review
Sponsor: Teva
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.